Trial Profile
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat Device in Patients With Cystic Fibrosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 01 Apr 2014 New trial record
- 04 Apr 2012
- 28 Jun 2011